The strong CARVYKTI sales growth and narrowing losses validate the commercial trajectory. Watch for upcoming medical conference data presentations on early-stage pipeline and any updates on profitability timeline. The $55M milestone from Janssen in April adds near-term cash buffer.
Price Chart
Executive Summary
Legend Biotech reported Q1 2026 revenue of $305.1M (vs $306.5M consensus, slight miss) and EPS of -$0.15 (GAAP) vs consensus -$0.17, a beat. CARVYKTI net trade sales surged 62% YoY to ~$597M, driving collaboration revenue up 61% to $298.4M. Net loss narrowed sharply to $54.3M from $101.0M a year ago, and adjusted net loss improved to $10.5M from $27.0M, signaling accelerating path to profitability.
Key Financial Metrics
Key Facts
- CARVYKTI net trade sales grew 62% YoY to ~$597M in Q1 2026
- Total revenue $305.1M vs $195.0M YoY (+56.5%)
- GAAP EPS -$0.15 vs consensus -$0.17 (beat)
- Net loss narrowed to $54.3M from $101.0M YoY
- Adjusted net loss improved to $10.5M from $27.0M YoY
- Cash and time deposits $834.6M, runway beyond 2026
- Manufacturing success rate reached 99%, on-time order releases >95%
- Achieved $55M in milestones from Janssen agreement in April 2026
- CARVYKTI now available in 18 global markets with >300 sites
Financial Impact
Revenue growth of $110.1M YoY (+56.5%), net loss improvement of $46.7M, adjusted net loss improvement of $16.5M
Risk Factors
- Revenue slightly below consensus ($305.1M vs $306.5M) despite strong growth
- Cost of collaboration revenue surged to $175.4M from $69.5M YoY due to capacity expansion costs
- Operating cash flow negative at -$85.1M, though improving from -$103.6M
- Dependence on single product CARVYKTI for revenue concentration
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292684 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | 6-K | $19.80 | awaiting T+20 | — | $19.27 (−2.68%) |
Oct 13, 2026 13d ago | 6-K | $17.88 | awaiting T+20 | — | $19.27 (+7.77%) |
Sep 29, 2026 27d ago | 144 | $18.82 | awaiting T+20 | — | $19.27 (+2.39%) |
Sep 25, 2026 4w ago | 6-K | $19.11 $19.27 | ▲ +0.84% | ▲ +2.31% | $19.27 (+0.84%) |
Sep 25, 2026 4w ago | Press Release | $19.11 $19.27 | ▲ +0.84% | ▲ +2.31% | $19.27 (+0.84%) |
Sep 15, 2026 5w ago | 6-K | $17.67 $17.88 | ▲ +1.19% | ▼ −1.53% | $19.27 (+9.05%) |
Sep 14, 2026 6w ago | 6-K | $18.53 $17.80 | ▼ −3.94% | ▼ −6.20% | $19.27 (+3.99%) |
Aug 11, 2026 10w ago | 6-K | $21.83 $19.91 | ▼ −8.80% | ▼ −7.74% | $19.27 (−11.73%) |
Jul 27, 2026 13w ago | 6-K | $19.27 $20.94 | ▼ −8.67% | ▼ −5.37% | $19.27 (−0.00%) |
Jul 27, 2026 13w ago | Press Release | $19.27 $20.94 | ▲ +8.67% | ▲ +5.37% | $19.27 (+0.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers